Ligand Pharmaceuticals Inc.

555 Heritage Drive
33458 Jupiter
USA

Kontakt WebSite

Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.

Beiträge

Ligand Pharmaceuticals übernimmt Apeiron Biologics
09.07.2024 • News

Ligand Pharmaceuticals übernimmt Apeiron Biologics

Apeiron gibt bekannt, dass ihre Aktionäre eine bindende Vereinbarung über den Verkauf ihrer Apeiron-Aktien an das US-amerikanische Unternehmen Ligand Pharmaceuticals für 100 Mio. USD getroffen haben.